Work

Abstract PS11-09: Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs20-ps11-09

Authors: Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O'Shaughnessy, Javier Cortés, Véronique Diéras, Lisa Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky

Institutions: UCSF Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Institut Curie, Universitair Ziekenhuis Leuven, Harvard University, Massachusetts General Hospital, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Centre Eugène Marquis, UNC Lineberger Comprehensive Cancer Center, Institut Jules Bordet, Immunomedics (United States), Columbia University Irving Medical Center

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3130820437

Cites:

Cited by: 13

Related to: 10